Cargando…
Genetic strategy to decrease complement activation with adenoviral therapies
BACKGROUND: A major obstacle to using recombinant adenoviral vectors in gene therapy is the natural ability of human adenovirus to activate the classical and alternate complement pathways. These innate immune responses contribute to hepatic adenoviral uptake following systemic delivery and enhance t...
Autores principales: | Gentile, Christopher M., Borovjagin, Anton V., Richter, Jillian R., Jani, Aditi H., Wu, Hongju, Zinn, Kurt R., Warram, Jason M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485611/ https://www.ncbi.nlm.nih.gov/pubmed/31026285 http://dx.doi.org/10.1371/journal.pone.0215226 |
Ejemplares similares
-
Using Multivalent Adenoviral Vectors for HIV Vaccination
por: Gu, Linlin, et al.
Publicado: (2013) -
Targeted adenoviral vectors
por: Vigne, E, et al.
Publicado: (2001) -
Adenoviral vector-based strategies against infectious disease and cancer
por: Zhang, Chao, et al.
Publicado: (2016) -
Improving adenoviral vectors and strategies for prostate cancer gene therapy
por: Tamura, Rodrigo Esaki, et al.
Publicado: (2018) -
Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors
por: Kreppel, Florian, et al.
Publicado: (2021)